PMID- 25003395
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140709
LR  - 20220408
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 6
IP  - 3
DP  - 2014 Jul 7
TI  - The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.
PG  - 1441-63
LID - 10.3390/cancers6031441 [doi]
AB  - The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
      pathway is one of the key signaling pathways induced by various receptor-tyrosine 
      kinases. Accumulating evidence shows that this pathway is an important promoter 
      of cell growth, metabolism, survival, metastasis, and resistance to chemotherapy. 
      Genetic alterations in the PI3K/Akt/mTOR pathway in gastric carcinoma have often 
      been demonstrated. Many kinds of molecular targeting therapies are currently 
      undergoing clinical testing in patients with solid tumors. However, with the 
      exception of the ErbB2-targeting antibody, targeting agents, including 
      PI3K/Akt/mTOR inhibitors, have not been approved for treatment of patients with 
      gastric carcinoma. This review summarizes the current knowledge on PI3K/Akt/mTOR 
      signaling in the pathogenesis of gastric carcinoma and the possible therapeutic 
      targets for gastric carcinoma. Improved knowledge of the PI3K/Akt/mTOR pathway in 
      gastric carcinoma will be useful in understanding the mechanisms of tumor 
      development and for identifying ideal targets of anticancer therapy for gastric 
      carcinoma.
FAU - Matsuoka, Tasuku
AU  - Matsuoka T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 
      m4808279@med.osaka-cu.ac.jp.
FAU - Yashiro, Masakazu
AU  - Yashiro M
AD  - Department of Surgical Oncology, Osaka City University Graduate School of 
      Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. 
      m9312510@med.osaka-cu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20140707
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC4190549
EDAT- 2014/07/09 06:00
MHDA- 2014/07/09 06:01
PMCR- 2014/07/07
CRDT- 2014/07/09 06:00
PHST- 2014/04/14 00:00 [received]
PHST- 2014/06/24 00:00 [revised]
PHST- 2014/06/26 00:00 [accepted]
PHST- 2014/07/09 06:00 [entrez]
PHST- 2014/07/09 06:00 [pubmed]
PHST- 2014/07/09 06:01 [medline]
PHST- 2014/07/07 00:00 [pmc-release]
AID - cancers6031441 [pii]
AID - cancers-06-01441 [pii]
AID - 10.3390/cancers6031441 [doi]
PST - epublish
SO  - Cancers (Basel). 2014 Jul 7;6(3):1441-63. doi: 10.3390/cancers6031441.